Structural Heart Devices Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 5.0 billion
Estimated Base Value
2035 Forecast
US$ 8.7 billion
Projected Market Value
CAGR 2026–2035
5.7%
Compound Annual Growth
Largest Segment
Transcatheter Aortic Valve Replacement Devices
Fastest Growing Segment
Transcatheter Mitral Valve Replacement Devices
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
30.0% market share
Key Players
Terumo Corporation
Emerging Players
Foldax, Cardiovalve
Market Definition & Overview
The Structural Heart Devices Market encompasses a range of specialized medical devices designed for the minimally invasive treatment and repair of structural heart diseases, including congenital defects, valvular disorders, and other anatomical abnormalities of the heart. This market primarily focuses on percutaneous and transcatheter-based interventions, offering alternatives to traditional open-heart surgery. It includes devices for valve repair and replacement, septal defect closure, and left atrial appendage occlusion, aiming to improve cardiac function and patient outcomes by addressing structural imperfections within the heart chambers, walls, and valves.
Scope
- Global market coverage across all major regions
- Analysis of various structural heart device product segments
- Market sizing and forecast from 2020 to 2030
Inclusions
- Transcatheter Aortic Valve Replacement (TAVR) devices
- Transcatheter Mitral Valve Repair/Replacement (TMVR) devices
- Left Atrial Appendage (LAA) closure devices
- Septal defect closure devices (ASD, PFO, VSD)
- Tricuspid valve repair/replacement devices
- Annuloplasty rings and prosthetic heart valves for structural interventions
Exclusions
- Traditional open-heart surgical instruments and procedures
- Pharmacological treatments for structural heart diseases
- Coronary artery disease (CAD) devices like coronary stents
- Electrophysiology devices such as pacemakers and defibrillators
- General cardiology diagnostic imaging equipment
Market Size Forecast
Executive Summary
• The Structural Heart Devices market is valued at $5.0 Bn in 2025 and is forecast to reach $8.7 Bn by 2035, reflecting a robust CAGR of 5.7% as demand accelerates across every major segment and region over the ten-year outlook.
• Transcatheter Aortic Valve Replacement Devices leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 33.0%, while Emerging Areas is expanding the fastest at a 9.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 30.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• Technological advancements in transcatheter therapies, particularly TAVR and TMVR, are significantly expanding treatable patient populations across all major regions, intensifying strategic focus on broader indication approvals and procedural efficiency.
• The competitive landscape is rapidly evolving through targeted M&A activities, as leading device manufacturers strategically integrate innovative start-ups to fortify their portfolios and gain market share in high-growth segments.
• Emerging economies, especially in APAC, represent critical growth frontiers, necessitating localized market access strategies, physician training, and cost-effective solutions to overcome reimbursement hurdles and expand treatment availability.
• Evolving clinical guidelines and favorable regulatory pathways are pivotal in expanding treatment eligibility, encouraging continued investment in robust clinical evidence generation to support next-generation device adoption across demographics.
• Beyond TAVR's mature growth, the emerging TMVR and tricuspid repair segments are poised for significant expansion, attracting substantial investment and fostering a new wave of disruptive device innovation for underserved patient groups.
• Strategic consolidation efforts among key players are reshaping market dynamics, prioritizing comprehensive structural heart portfolios to optimize hospital partnerships and secure long-term global market leadership positions.
Key Market Takeaways
Critical findings and data points from this market research study.
Market Valuation
The Structural Heart Devices Market was valued at a significant $5.0 billion in the base year, establishing its current market scale.
Projected Growth
The market is projected to expand substantially, reaching $8.7 billion by the forecast year, indicating strong future demand.
Healthy CAGR
This growth trajectory translates to a Compound Annual Growth Rate (CAGR) of 5.7%, underscoring a steady and promising market expansion.
Leading Segment
The Transcatheter Aortic Valve Replacement (TAVR) segment is anticipated to continue its dominance, driving significant market revenue due to its growing adoption.
Regional Leadership
North America is expected to maintain its leadership in market share, propelled by advanced healthcare infrastructure and high adoption rates of novel devices.
Innovation Trend
A key market trend is the continuous innovation in minimally invasive procedures and next-generation device development, enhancing treatment efficacy and patient outcomes.
Market Dynamics
Market Trends
- Shift towards minimally invasive structural heart procedures continues.
- Rapid technological advancements improve device efficacy and safety.
- Increasing adoption of transcatheter mitral and tricuspid valve therapies.
- Real-world evidence and data analytics are enhancing clinical outcomes.
Growth Drivers
- Growing global prevalence of structural heart diseases fuels demand.
- Aging population significantly increases patient pool for interventions.
- Improved diagnostic techniques lead to earlier disease detection.
- Favorable reimbursement policies encourage market expansion and access.
Restraints
- High device and procedure costs limit market accessibility.
- Stringent regulatory processes delay market entry for innovations.
- Potential for procedural complications remains a key challenge.
- Limited access to specialized centers and skilled professionals constrains growth.
Opportunities
- Significant growth potential in developing and emerging economies.
- Innovation in novel devices for complex structural heart conditions.
- Expansion into pediatric structural heart interventions offers new niche.
- Telemedicine and remote monitoring enhance post-procedure patient care.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Transcatheter Aortic Valve Replacement DevicesTranscatheter Mitral Valve Repair DevicesTranscatheter Mitral Valve Replacement DevicesTranscatheter Tricuspid Valve Repair & Replacement DevicesPatent Foramen Ovale Closure DevicesAtrial Septal Defect Closure DevicesVentricular Septal Defect Closure DevicesLeft Atrial Appendage Closure Devices |
| By Technology | Self-Expandable Valve TechnologiesBalloon-Expandable Valve TechnologiesTranscatheter Mitral Annuloplasty TechnologiesTranscatheter Chordal Repair TechnologiesPercutaneous Septal Occlusion TechnologiesPercutaneous Left Atrial Appendage Occlusion TechnologiesSurgical Valve Repair & Replacement Technologies |
| By Application | Aortic Stenosis TreatmentMitral Regurgitation TreatmentMitral Stenosis TreatmentTricuspid Regurgitation TreatmentPatent Foramen Ovale RepairAtrial Septal Defect RepairVentricular Septal Defect RepairLeft Atrial Appendage Stroke Prevention |
| By End-User | HospitalsSpecialty Cardiology ClinicsAmbulatory Surgical CentersAcademic & Research Institutes |
| By Component | Implantable ValvesImplantable Occluder DevicesTranscatheter Delivery SystemsAccessory Devices |
| By Material Type | NitinolPolymers & FabricsBioprosthetic TissueCobalt Chromium AlloyStainless SteelPlatinum Iridium AlloyOther Alloys & Composites |
Regional Analysis
- North America dominates the structural heart devices market due to high prevalence of cardiovascular diseases, robust healthcare infrastructure, and strong reimbursement policies. Its focus on technological advancements and early adoption of innovative treatments further solidifies its leading position in this medical device sector.
- Asia Pacific is the fastest-growing region, driven by its large and aging population, increasing prevalence of heart diseases, and improving healthcare infrastructure. Rising disposable incomes, growing medical tourism, and government investments in healthcare further fuel market expansion and adoption of advanced devices.
- In Europe, a noteworthy trend is the increasing adoption of transcatheter mitral valve repair (TMVR) and replacement (TMVR) procedures, driven by an aging population and favorable clinical outcomes. There's also a growing focus on cost-effectiveness and value-based care within the structural heart device market.
Asia Pacific
8.5% CAGR
$1.7 Bn
33% share
- This region is poised for significant growth, driven by a large and aging population, increasing healthcare expenditure, and improving medical infrastructure, particularly in China and India.
North America
6.0% CAGR
$1.5 Bn
30% share
- A highly mature market with advanced healthcare infrastructure, strong reimbursement policies, and high adoption rates of innovative structural heart devices, supported by a significant aging demographic.
Europe
5.5% CAGR
$1.3 Bn
25% share
- Characterized by an aging population and well-established healthcare systems, this region maintains a substantial market share, though growth may be moderate due to market maturity and varying national healthcare policies.
Latin America
7.5% CAGR
$350.0 Mn
7% share
- Experiencing accelerating growth due to increasing healthcare investments, rising awareness of cardiovascular diseases, and expanding access to advanced medical treatments in major economies like Brazil and Mexico.
Middle East & Africa
8.0% CAGR
$175.0 Mn
3.5% share
- Growth is propelled by rising healthcare expenditure in the Middle East and improving economic conditions in certain African nations, alongside an increasing prevalence of cardiovascular conditions, despite significant regional disparities.
Emerging Areas
9.0% CAGR
$75.0 Mn
1.5% share
- Though starting from a smaller base, these nascent markets show high growth potential as healthcare infrastructure develops and access to advanced medical devices gradually improves across underserved geographies.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $1.5 Bn | 6.5% | The U.S. remains the largest and most mature market for structural heart devices, driven by a high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and continuous innovation in treatment technologies. |
| 2 | Brazil | $90.0 Mn | 8.0% | As the largest economy in South America, Brazil shows significant potential due to its large population, increasing incidence of cardiovascular diseases, and expanding public and private healthcare investments. |
| 3 | Germany | $350.0 Mn | 5.5% | Germany is a leading European market, propelled by its robust healthcare system, high research and development spending, and widespread adoption of cutting-edge structural heart repair and replacement technologies. |
| 4 | China | $475.0 Mn | 10.5% | China is a rapidly expanding market for structural heart devices, driven by its massive patient population, increasing healthcare spending, and significant investments in local manufacturing and technology adoption. |
| 5 | Saudi Arabia | $30.0 Mn | 8.5% | Saudi Arabia is a key market in the region, driven by significant government investment in healthcare infrastructure, increasing prevalence of cardiovascular diseases, and a growing medical tourism sector. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, United Kingdom, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Terumo Corporation | 5.7% | Focus on providing comprehensive solutions for complex cardiovascular interventions, including structural heart, leveraging advanced interventional tools. | A diversified global medical device manufacturer with strong R&D capabilities and a broad portfolio across cardiovascular and other therapeutic areas. | Ongoing expansion of their interventional cardiology product lines and market reach in Asia and Europe. | Aquacore TAVI SystemHeartrail Guiding CathetersFineCross MG Micro-Catheter |
| 2 | LivaNova | 5.4% | Innovate in less invasive cardiac surgery solutions and neuromodulation, focusing on high-growth segments after portfolio streamlining. | Known for its sutureless heart valve technology, offering a less invasive surgical option for aortic valve replacement. | Received FDA approval for its Perceval Plus sutureless aortic heart valve, enhancing its structural heart offering. | Perceval Plus Sutureless Aortic Heart ValveSorin Bicarbon Aortic ValveMemphis Perfusion System |
| 3 | MicroPort Scientific | 5.1% | Drive innovation in high-growth medical device markets, particularly structural heart, with a strong focus on the Chinese market and international expansion. | A leading Chinese medical device company with a rapidly expanding global presence, especially notable for its VitaFlow TAVI system. | Successfully launched its VitaFlow Liberty TAVI system in multiple international markets, expanding its global footprint. | VitaFlow Liberty TAVI SystemReAortic Aortic ValveFirehawk Coronary Stent |
| 4 | Getinge | 4.9% | Provide high-quality medical technology and solutions primarily for surgery, intensive care, and sterile reprocessing, supporting critical care environments. | A global provider of equipment and systems for hospitals and life sciences institutions, not primarily a structural heart device manufacturer but a key supplier for cardiac surgical environments. | Launched the new Flow-e oxygenator, enhancing its life support solutions for critical care including cardiac procedures. | Cardiohelp SystemMaquet Datascope IABPJostra HL 20 Heart-Lung Machine |
| 5 | Meril Life Sciences | 4.6% | Develop affordable, high-quality medical devices for cardiovascular care, focusing on emerging markets and expanding global presence. | An Indian innovator making significant inroads in the global structural heart market with its TAVI system. | Expanded the commercial availability of its MyVal TAVI system to new European and Asian markets. | MyVal TAVI SystemMeRes100 Sirolimus Eluting Coronary StentMilo AF Ablation Catheter |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Terumo Corporation, LivaNova, MicroPort Scientific, Getinge, Meril Life Sciences, Venus Medtech, Lepu Medical, JenaValve Technology, Sahajanand Medical Technologies (SMT), Occlutech, HighLife Medical, New Valve Technology (NVT), Anteris Technologies, NeoChord, Cardiac Dimensions, Braile Biomedica, Beijing Balance Medical Technology, Valgen Medtech, V-Wave Ltd, 4C Medical
The global Structural Heart Devices market features a competitive landscape led by Terumo Corporation, LivaNova, MicroPort Scientific, Getinge, Meril Life Sciences, and Venus Medtech, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Terumo Corporation
LivaNova
MicroPort Scientific
Getinge
Meril Life Sciences
Venus Medtech
Lepu Medical
JenaValve Technology
Sahajanand Medical Technologies (SMT)
Occlutech
HighLife Medical
New Valve Technology (NVT)
Anteris Technologies
NeoChord
Cardiac Dimensions
Braile Biomedica
Beijing Balance Medical Technology
Valgen Medtech
V-Wave Ltd
4C Medical
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Medtronic Launches Latest Generation Self-Expanding TAVR System
Medtronic announced the global launch of its newest transcatheter aortic valve replacement (TAVR) system, featuring enhanced design for improved conformability and expanded size range. This launch aims to reinforce its competitive position in the rapidly evolving TAVR market.
Abbott Acquires Innovative Tricuspid Valve Repair Specialist
Abbott announced the acquisition of ValuFix Medical, a privately held company developing a novel transcatheter tricuspid valve repair system. This strategic move strengthens Abbott's leadership in structural heart interventions, particularly in addressing unmet needs in tricuspid valve disease.
Edwards SAPIEN X4 TAVR System Receives CE Mark and European Launch
Edwards Lifesciences announced CE Mark approval and immediate European launch of its SAPIEN X4 transcatheter aortic valve replacement system, designed for even lower profile delivery and improved patient outcomes. This milestone solidifies Edwards' continued innovation and market leadership in the European TAVR landscape.
Strategic Investment Fuels Development of Novel Transcatheter Mitral Repair Device
A consortium led by XYZ Ventures and including strategic investment from a leading structural heart device manufacturer announced a significant funding round for CardioInnovate Inc., a startup developing a groundbreaking transcatheter mitral valve repair technology. This investment will accelerate clinical trials and market access for the innovative device.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $5.0 Bn |
| Market Size (Forecast) | $8.7 Bn |
| CAGR | 5.7% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 38 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included